| Literature DB >> 21214892 |
Elizabeth Juma1, Dejan Zurovac.
Abstract
BACKGROUND: Change of Kenyan treatment policy for uncomplicated malaria from sulphadoxine-pyrimethamine to artemether-lumefantrine (AL) was accompanied by revised recommendations promoting presumptive malaria diagnosis in young children and, wherever possible, parasitological diagnosis and adherence to test results in older children and adults. Three years after the policy implementation, health workers' adherence to malaria diagnosis and treatment recommendations was evaluated.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21214892 PMCID: PMC3022768 DOI: 10.1186/1475-2875-10-1
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Malaria testing rates for febrile patients under and over 5 years of age
| All health facilities | Aged < 5 years | Aged ≥ 5 years | All age groups | |||
|---|---|---|---|---|---|---|
| n (%) | 95% CI | n (%) | 95% CI | n (%) | 95% CI | |
| Tested for malaria | 193 (19.8) | 14.3-25.3 | 288 (28.7) | 21.8-35.7 | 481 (24.3) | 19.0-29.7 |
| Tested for malaria | 190 (33.5) | 25.1-42.0 | 284 (53.7) | 45.4-61.9 | 474 (43.2) | 36.4-50.1 |
Anti-malarial treatment practices for febrile children under 5 years of age stratified by the availability of diagnostics, use and result of malaria test
| Children aged < 5 years | Health facilities with diagnostics | Health facilities without diagnostics | All health facilities | ||
|---|---|---|---|---|---|
| 68 (74.7) | 40 (40.4) | 229 (60.7) | 282 (69.3) | 619 (63.6) | |
| 17 (18.7) | 6 (6.1) | 22 (5.8) | 16 (4.0) | 61 (6.3)* | |
| 5 (5.5) | 3 (3.0) | 10 (2.7) | 8 (2.0) | 26 (2.7) | |
| 0 | 5 (5.1) | 8 (2.1) | 1 (0.3) | 14 (1.4) | |
| 0 | 2 (2.0) | 4 (1.1) | 0 | 6 (0.6) | |
| 1 (1.1) | 0 | 0 | 0 | 1 (0.1) | |
| 0 | 43 (43.4) | 104 (27.6) | 100 (24.6) | 247 (25.4) | |
| 91 (100) | 56 (56.6) | 273 (72.4) | 307 (75.4) | 727 (74.6) | |
| 70 (76.9) | 89 (89.9) | 281 (74.5) | 329 (80.8) | 769 (79.0) | |
*All QN treatments as part of AL+QN therapy include administration of injectable quinine
AL, artemether-lumefantrine; AQ, amodiaquine; SP, sulphadoxine-pyrimethamine; QN, quinine; AM, anti-malarial.
Anti-malarial treatment practices for febrile patients 5 years and older stratified by the availability of diagnostics, use and result of malaria test
| Health facilities with diagnostics | Health facilities without diagnostics | All health facilities | |||
|---|---|---|---|---|---|
| 143 (86.7) | 39 (32.8) | 142 (58.0) | 327 (69.1) | 651 (65.0) | |
| 1 (0.6) | 16 (13.5) | 9 (3.7) | 12 (2.5) | 38 (3.8) | |
| 12 (7.3) | 2 (1.7) | 0 | 16 (3.4) | 30 (3.0)* | |
| 6 (3.6) | 2 (1.7) | 1 (0.4) | 7 (1.5) | 16 (1.6) | |
| 0 | 1 (0.8) | 0 | 0 | 1 (0.1) | |
| 1 (0.6) | 0 | 1 (0.4) | 2 (0.4) | 4 (0.4) † | |
| 2 (1.2) | 59 (49.6) | 92 (37.6) | 109 (23.0) | 262 (26.2) | |
| 163 (98.8) | 60 (50.4) | 153 (62.5) | 364 (77.0) | 740 (73.9) | |
| 90 (54.6) | 92 (82.4) | 169 (69.0) | 333 (70.4) | 690 (68.9) | |
*All QN treatments include administration of injectable quinine
† Other anti-malarial treatment included dihydroartemisinin (2), QN+SP (1) and AL+SP (1).
AL, artemether-lumefantrine; AQ, amodiaquine; SP, sulphadoxine-pyrimethamine; QN, quinine; AM, anti-malarial.